AstraZeneca Reports Strong Q1 2025 Growth

AstraZeneca ( (AZN) ) has released its Q1 earnings. Here is a breakdown of the information AstraZeneca presented to its investors.

AstraZeneca, a leading pharmaceutical company, specializes in the research, development, and manufacturing of innovative medicines, with a strong focus on oncology and biopharmaceuticals. In its latest earnings report for Q1 2025, AstraZeneca showcased robust growth, driven by significant advancements in its oncology and biopharmaceutical sectors. The company reported a 10% increase in total revenue, reaching $13,588 million, with core EPS rising by 21% to $2.49. Key growth drivers included double-digit revenue increases in oncology and biopharmaceuticals, alongside five positive Phase III study readouts and 13 regulatory approvals in major regions. AstraZeneca’s strategic focus on expanding its global manufacturing and R&D footprint, particularly in the US, is evident with planned investments in manufacturing and research facilities. Looking ahead, AstraZeneca remains optimistic about achieving its ambitious goal of $80 billion in total revenue by 2030, supported by its strong pipeline and strategic growth initiatives.